(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Improving as a Cook: Culinary Experiences in the Kitchen - 2Overlooked infertility care should be part of national health services, says WHO
- 310 Setting up camp Shelters That Offer Both Excellence and Isolation
- 4She was moments away from giving birth. The hospital discharged her
- 56 Trail blazing Bicycles for Rough terrain Undertakings
- Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- Opening Potential: Self-awareness and Long lasting Learning
- Scientists discover black hole flare with the light of 10 trillion suns
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- Pick Your Favored method of transportation
- Well known Worldwide Caf\u00e9s to Experience
- Find Successful Magnificence Items for Sparkling Skin
- 2024 Eurovision winner Nemo returns trophy over Israel's participation
- Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
